Good news for women who have platinum-resistant OC and who have had 5 previous types of treatment.
The drug, STRO-002 is a combination antibody-drug conjugate, meaning it combines an antibody with chemo to deliver the medication directly to the cancer cell, hopefully eliminating some adverse side effects associated with off-targeting.
The results were presented at 2020 AACR Virtual Meeting of April 27-28.
Phase1 has been successfully completed which means that the toxic range of the medication has been established and now, Phase 2, will determine the recommended dose. OncLive conducted an interview with one of the lead investigators. Follow this link to the full article.
In October 2012, a dream was realized for two dynamic ovarian cancer survivors: Anne Tonachel and Robin Bray. Their dream was to provide a restorative retreat for other ovarian cancer survivors in the northeast. When the amazing Kennedy family of Camp Kieve and The Kennedy Learning Center provided the retreat space (in honor of a family member with ovarian cancer), this restorative retreat was born.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment